NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$82.93 +1.54 (+1.89 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$82.93
Today's Range$80.2833 - $84.47
52-Week Range$51.05 - $135.59
Volume1.20 million shs
Average Volume576,332 shs
Market Capitalization$2.45 billion
P/E Ratio-5.77
Dividend YieldN/A
Beta-1.78

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Debt-to-Equity Ratio-6.88
Current Ratio4.58
Quick Ratio4.58

Price-To-Earnings

Trailing P/E Ratio-5.77
Forward P/E Ratio-7.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$130.96 million
Price / Sales18.73
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book127.58

Profitability

EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-241.33%
Return on Equity-573.64%
Return on Assets-68.54%

Miscellaneous

Employees507
Outstanding Shares29,580,000

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) released its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($3.22) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($3.41) by $0.19. The biopharmaceutical company had revenue of $35.96 million for the quarter, compared to the consensus estimate of $38.44 million. Intercept Pharmaceuticals had a negative return on equity of 573.64% and a negative net margin of 241.33%. Intercept Pharmaceuticals's revenue for the quarter was up 70.9% on a year-over-year basis. During the same quarter last year, the business posted ($3.61) EPS. View Intercept Pharmaceuticals' Earnings History.

What price target have analysts set for ICPT?

21 analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their predictions range from $50.00 to $253.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $124.4737 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, "PBC – Despite headwinds associated with labeling harmonization for Ocaliva and widened gross-to-net impact expected for the earlier portion of the year, scripts for the drug have been reported to have stabilized. We believe efforts towards educating and creating confidence for prescribing physicians may have stemmed the tide and signal the return to revenue growth. While our long-term projections remain conservative (20% at peak), continued execution in the remainder of 2018 could build our confidence and expand opportunity for the shares. That said, we remain cautious on NASH." (5/8/2018)
  • 2. According to Zacks Investment Research, "Intercept’s fourth-quarter results missed expectations as sales of Ocaliva declined due to safety issues surrounding the drug. The approval of Ocaliva was a significant boost for Intercept. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. The company also announced an updated label for Ocaliva in the United States, reinforcing appropriate dosing in PBC patients with Child-P Class B or C or decompensated cirrhosis. While the updated label should help the stock turn around, it might be a while before the sales start to recover. First-quarter is expected to be a transitional quarter. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC. Given the challenges faced by the drug in recent times, the label expansion of OCA will boost the growth prospects. Shares have underperformed the industry in the last six months." (2/19/2018)
  • 3. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
  • 4. Wells Fargo & Co analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
  • Dr. David Shapiro M.D., Ph.D., Chief Medical Officer (Age 64)
  • Ms. Lisa Bright B.Sc., Pres of International (Age 50)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 50)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

Headlines about ICPT stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 0.13 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.80 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include GENEXTRA S.P.A. (23.30%), Senvest Management LLC (3.89%), BB Biotech AG (1.84%), Altrinsic Global Advisors LLC (1.27%), Elk Creek Partners LLC (1.18%) and Melqart Asset Management UK Ltd (1.01%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which institutional investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, A.R.T. Advisors LLC, Guggenheim Capital LLC, Pinnacle Associates Ltd., LPL Financial LLC, BNP Paribas Arbitrage SA, Teacher Retirement System of Texas and State Board of Administration of Florida Retirement System. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was bought by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Point72 Asset Management L.P., Senvest Management LLC, Millennium Management LLC, Melqart Asset Management UK Ltd, Scopia Capital Management LP, Altrinsic Global Advisors LLC and BB Biotech AG. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $82.93.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $2.45 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  785 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  1,197
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Intercept Pharmaceuticals in the last 12 months. Their average twelve-month price target is $124.4737, suggesting that the stock has a possible upside of 50.09%. The high price target for ICPT is $253.00 and the low price target for ICPT is $50.00. There are currently 3 sell ratings, 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.332.36
Ratings Breakdown: 3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $124.4737$124.4737$128.3684$141.35
Price Target Upside: 50.09% upside74.35% upside97.43% upside133.10% upside

Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History

Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018WedbushReiterated RatingBuyMediumView Rating Details
5/9/2018CowenReiterated RatingBuy$88.00LowView Rating Details
5/8/2018OppenheimerReiterated RatingHoldHighView Rating Details
5/8/2018Cantor FitzgeraldReiterated RatingHold$58.00LowView Rating Details
3/28/2018Needham & Company LLCReiterated RatingHoldMediumView Rating Details
2/15/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$152.00 ➝ $155.00HighView Rating Details
2/13/2018Wells Fargo & CoReiterated RatingMarket Perform$62.00 ➝ $57.00MediumView Rating Details
2/12/2018Deutsche BankInitiated CoverageBuy$103.00MediumView Rating Details
2/7/2018Goldman Sachs GroupDowngradeNeutral ➝ SellLowView Rating Details
1/25/2018Robert W. BairdReiterated RatingOutperform$332.00 ➝ $253.00LowView Rating Details
1/22/2018Credit Suisse GroupSet Price TargetBuy$201.00 ➝ $167.00HighView Rating Details
12/29/2017CitigroupSet Price TargetHold$74.00HighView Rating Details
11/28/2017Leerink SwannReiterated RatingHold$60.00LowView Rating Details
11/1/2017LaidlawUpgradeHold ➝ Buy$90.00N/AView Rating Details
10/13/2017Bank of AmericaLower Price TargetUnderperform$102.00 ➝ $73.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/AView Rating Details
10/4/2017Royal Bank of CanadaReiterated RatingOutperform ➝ OutperformHighView Rating Details
10/4/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformHighView Rating Details
9/26/2017Jefferies Financial GroupReiterated RatingBuy$275.00 ➝ $135.00LowView Rating Details
9/22/2017UBS GroupDowngradeOutperform ➝ Market PerformLowView Rating Details
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 ➝ $50.00HighView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
(Data available from 6/17/2016 forward)

Earnings

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings History and Estimates Chart

Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings Estimates

2018 EPS Consensus Estimate: ($11.90)
2019 EPS Consensus Estimate: ($9.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($3.71)($3.32)($3.46)
Q2 20185($3.39)($2.71)($2.89)
Q3 20184($3.01)($2.55)($2.74)
Q4 20184($3.14)($2.58)($2.82)
Q1 20191($2.57)($2.57)($2.57)
Q2 20191($2.40)($2.40)($2.40)
Q3 20191($2.18)($2.18)($2.18)
Q4 20191($1.98)($1.98)($1.98)

Intercept Pharmaceuticals (NASDAQ ICPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($3.41)($3.22)$38.44 million$35.96 millionViewN/AView Earnings Details
2/14/2018Q4 2017($3.39)($4.43)$39.01 million$37.69 millionViewN/AView Earnings Details
11/1/2017Q3 2017($3.48)($2.89)$36.95 million$41.33 millionViewN/AView Earnings Details
7/31/2017Q2 2017($3.62)($3.46)$27.50 million$30.89 millionViewN/AView Earnings Details
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)$0.41 million$0.41 millionViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 million$0.41 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.4050 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.44)($0.62)$1.23 million$0.41 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.37)($0.43)ViewN/AView Earnings Details
11/26/2012Q3 2012($0.57)($1.86)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Intercept Pharmaceuticals (NASDAQ:ICPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 66.35%
Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/9/2018Francesco MicheliMajor ShareholderBuy390,625$64.00$25,000,000.00View SEC Filing  
4/9/2018Keith Michael GottesdienerDirectorBuy1,171$64.00$74,944.005,001View SEC Filing  
4/9/2018Mark PruzanskiCEOBuy7,812$64.00$499,968.0011,642View SEC Filing  
10/2/2017David ShapiroCMOSell349$58.90$20,556.10View SEC Filing  
10/2/2017Mark PruzanskiCEOSell1,532$58.87$90,188.84View SEC Filing  
10/2/2017Rachel McminnInsiderSell283$58.89$16,665.87View SEC Filing  
10/2/2017Richard J KimSVPSell48$58.10$2,788.80View SEC Filing  
10/2/2017Sandip KapadiaCFOSell354$58.83$20,825.82View SEC Filing  
9/1/2017David ShapiroCMOSell1,250$117.43$146,787.5045,812View SEC Filing  
8/25/2017Lisa BrightInsiderSell253$111.31$28,161.4323,324View SEC Filing  
8/2/2017Lisa BrightInsiderSell142$110.29$15,661.1823,477View SEC Filing  
8/1/2017David ShapiroCMOSell1,118$119.00$133,042.0045,680View SEC Filing  
7/31/2017Daniel G WelchDirectorSell602$123.93$74,605.863,108View SEC Filing  
7/31/2017Rachel McminnInsiderSell130$123.12$16,005.6017,158View SEC Filing  
7/20/2017Daniel G WelchDirectorSell217$126.76$27,506.923,710View SEC Filing  
7/14/2017Richard J KimSVPSell89$128.64$11,448.9611,253View SEC Filing  
7/11/2017David ShapiroCMOSell553$124.01$68,577.5344,562View SEC Filing  
7/3/2017David ShapiroCMOSell350$121.24$42,434.0045,215View SEC Filing  
7/3/2017Lisa BrightInsiderSell394$121.33$47,804.0223,619View SEC Filing  
7/3/2017Mark PruzanskiCEOSell1,434$121.78$174,632.52570,284View SEC Filing  
7/3/2017Richard J KimSVPSell50$121.69$6,084.5011,342View SEC Filing  
7/3/2017Sandip KapadiaCFOSell1,431$121.59$173,995.2920,569View SEC Filing  
6/26/2017Mark PruzanskiCEOSell40,000$130.80$5,232,000.00611,718View SEC Filing  
6/1/2017Lisa BrightInsiderSell698$110.73$77,289.5424,711View SEC Filing  
5/25/2017Lisa BrightInsiderSell254$117.52$29,850.0823,246View SEC Filing  
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.6223,613View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.0023,804View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.0646,582View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.6817,545View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.5845,465View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.0046,023View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.0022,925View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00571,718View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.9221,695View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.6417,383View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.6540,369View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.9641,934View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84552,705View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.7212,916View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.5042,922View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.4018,209View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.7813,732View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.7444,272View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.4030,661View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.0446,196View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.0018,305View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00552,020View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.6045,732View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00579,314View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.0018,460View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.2513,861View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.5018,855View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.7014,087View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.4430,948View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.4048,546View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.2819,106View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08548,248View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.0219,259View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.687,621View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.5611,700View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.2024,892View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.7040,911View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40529,556View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.107,749View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.0012,428View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.9228,395View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.0029,159View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.002,166View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.008,218View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.1824,062View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.8029,159View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86962View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.0023,527View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00470,174View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00470,174View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.0013,510View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.781,640View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.007,041View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.1913,679View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.4413,124View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.961,655View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00430,298View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.001,943View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.808,663View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.991,640View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.946,392View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.763,000View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.005,094View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00402,032View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00402,032View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.005,094View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.204,266View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.162,532View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00402,032View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.671,330View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Intercept Pharmaceuticals Inc (ICPT) to Announce -$2.94 Earnings Per Share Brokerages Anticipate Intercept Pharmaceuticals Inc (ICPT) to Announce -$2.94 Earnings Per Share
www.americanbankingnews.com - June 16 at 11:46 AM
Intercept Pharmaceuticals (ICPT) Receives Average Rating of "Hold" from AnalystsIntercept Pharmaceuticals (ICPT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - June 14 at 12:21 PM
Todays Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Intercept PharmaceuticalsToday's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Intercept Pharmaceuticals
finance.yahoo.com - June 13 at 8:40 AM
Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver DiseasesIntercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases
seekingalpha.com - June 12 at 4:49 PM
Interesting ICPT Put And Call Options For June 2019Interesting ICPT Put And Call Options For June 2019
www.nasdaq.com - June 12 at 4:49 PM
Intercept Pharmaceuticals: Buyout Speculation Stokes SharesIntercept Pharmaceuticals: Buyout Speculation Stokes Shares
seekingalpha.com - June 12 at 8:39 AM
Today’s Research Reports on Stocks to Watch: TapImmune and Intercept PharmaceuticalsToday’s Research Reports on Stocks to Watch: TapImmune and Intercept Pharmaceuticals
finance.yahoo.com - June 11 at 8:38 AM
Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue?Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 7 at 5:01 PM
Court Appoints Faruqi & Faruqi, LLP As Lead Counsel For Class Action Against Intercept Pharmaceuticals, Inc.Court Appoints Faruqi & Faruqi, LLP As Lead Counsel For Class Action Against Intercept Pharmaceuticals, Inc.
www.bizjournals.com - June 5 at 5:05 PM
Reader Inquiry: Whats The Updated Outlook For CymaBay Therapeutics?Reader Inquiry: What's The Updated Outlook For CymaBay Therapeutics?
seekingalpha.com - June 3 at 8:39 AM
Madrigal Soars 144% On NASH Results, Is There Room To Run Higher?Madrigal Soars 144% On NASH Results, Is There Room To Run Higher?
seekingalpha.com - June 1 at 8:53 AM
Analysts Are Bullish on Viking Therapeutics StockAnalysts Are Bullish on Viking Therapeutics Stock
finance.yahoo.com - June 1 at 8:53 AM
Intercept Pharmaceuticals (ICPT) Expected to Announce Quarterly Sales of $40.05 MillionIntercept Pharmaceuticals (ICPT) Expected to Announce Quarterly Sales of $40.05 Million
www.americanbankingnews.com - June 1 at 4:52 AM
Noteworthy Thursday Option Activity: MCD, ICPT, THONoteworthy Thursday Option Activity: MCD, ICPT, THO
www.nasdaq.com - May 31 at 5:10 PM
Intercept Pharma down 6% premarket on positive Madrigal NASH dataIntercept Pharma down 6% premarket on positive Madrigal NASH data
seekingalpha.com - May 31 at 8:57 AM
Zacks: Analysts Anticipate Intercept Pharmaceuticals (ICPT) to Post -$2.94 EPSZacks: Analysts Anticipate Intercept Pharmaceuticals (ICPT) to Post -$2.94 EPS
www.americanbankingnews.com - May 30 at 1:20 AM
Intercept Pharmaceuticals (ICPT) Could See Upside on Upcoming Competitor NASH Data - RBCIntercept Pharmaceuticals (ICPT) Could See Upside on Upcoming Competitor NASH Data - RBC
www.streetinsider.com - May 24 at 8:41 AM
FY2018 EPS Estimates for Intercept Pharmaceuticals (ICPT) Lifted by Cantor FitzgeraldFY2018 EPS Estimates for Intercept Pharmaceuticals (ICPT) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - May 24 at 8:36 AM
Intercept Pharmaceuticals (ICPT) Given Average Rating of "Hold" by AnalystsIntercept Pharmaceuticals (ICPT) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 20 at 8:14 AM
Notable Friday Option Activity: ICPT, JNJ, CELGNotable Friday Option Activity: ICPT, JNJ, CELG
www.nasdaq.com - May 18 at 5:26 PM
Intercept Pharmaceuticals (ICPT) "Buy" Rating Reiterated at WedbushIntercept Pharmaceuticals' (ICPT) "Buy" Rating Reiterated at Wedbush
www.americanbankingnews.com - May 18 at 4:45 PM
Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathans Famous, United Fire Group, and Intercept Pharmaceuticals — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals — Future Expectations, Projections Moving into 2018
finance.yahoo.com - May 18 at 9:15 AM
Intercept Pharmaceuticals Forecasted to Post Q2 2018 Earnings of ($2.71) Per Share (ICPT)Intercept Pharmaceuticals Forecasted to Post Q2 2018 Earnings of ($2.71) Per Share (ICPT)
www.americanbankingnews.com - May 18 at 7:30 AM
ValuEngine Downgrades Intercept Pharmaceuticals (ICPT) to Strong SellValuEngine Downgrades Intercept Pharmaceuticals (ICPT) to Strong Sell
www.americanbankingnews.com - May 17 at 4:41 PM
Wedbush Weighs in on Intercept Pharmaceuticals Q1 2019 Earnings (ICPT)Wedbush Weighs in on Intercept Pharmaceuticals' Q1 2019 Earnings (ICPT)
www.americanbankingnews.com - May 17 at 8:48 AM
 Analysts Anticipate Intercept Pharmaceuticals (ICPT) Will Post Quarterly Sales of $39.42 Million Analysts Anticipate Intercept Pharmaceuticals (ICPT) Will Post Quarterly Sales of $39.42 Million
www.americanbankingnews.com - May 15 at 4:58 AM
Seaport Global Securities Weighs in on Intercept Pharmaceuticals Q2 2018 Earnings (ICPT)Seaport Global Securities Weighs in on Intercept Pharmaceuticals' Q2 2018 Earnings (ICPT)
www.americanbankingnews.com - May 14 at 2:18 AM
Intercept Pharmaceuticals (ICPT) Expected to Announce Earnings of -$3.06 Per ShareIntercept Pharmaceuticals (ICPT) Expected to Announce Earnings of -$3.06 Per Share
www.americanbankingnews.com - May 13 at 1:20 AM
Intercept Pharmaceuticals (ICPT) Earns Buy Rating from WedbushIntercept Pharmaceuticals (ICPT) Earns Buy Rating from Wedbush
www.americanbankingnews.com - May 11 at 7:05 PM
Jefferies Group Comments on Intercept Pharmaceuticals Q2 2018 Earnings (ICPT)Jefferies Group Comments on Intercept Pharmaceuticals' Q2 2018 Earnings (ICPT)
www.americanbankingnews.com - May 11 at 9:41 AM
Intercept Pharmaceuticals Forecasted to Post Q2 2018 Earnings of ($2.75) Per Share (ICPT)Intercept Pharmaceuticals Forecasted to Post Q2 2018 Earnings of ($2.75) Per Share (ICPT)
www.americanbankingnews.com - May 11 at 9:41 AM
Oppenheimer Weighs in on Intercept Pharmaceuticals Q2 2018 Earnings (ICPT)Oppenheimer Weighs in on Intercept Pharmaceuticals' Q2 2018 Earnings (ICPT)
www.americanbankingnews.com - May 11 at 9:39 AM
Analysts Anticipate 14% Upside For FXHAnalysts Anticipate 14% Upside For FXH
www.nasdaq.com - May 10 at 5:26 PM
Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance ...Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance ...
globenewswire.com - May 10 at 5:26 PM
BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 ...BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 ...
www.reuters.com - May 10 at 5:26 PM
Edited Transcript of ICPT earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of ICPT earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:52 AM
Intercept Pharmaceuticals (ICPT) Receives Buy Rating from CowenIntercept Pharmaceuticals (ICPT) Receives Buy Rating from Cowen
www.americanbankingnews.com - May 9 at 9:42 PM
Intercept Pharmaceuticals (ICPT) Receives Hold Rating from OppenheimerIntercept Pharmaceuticals (ICPT) Receives Hold Rating from Oppenheimer
www.americanbankingnews.com - May 9 at 12:08 PM
Intercept Pharmaceuticals (ICPT) Q1 2018 Results - Earnings Call TranscriptIntercept Pharmaceuticals (ICPT) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:11 PM
Cantor Fitzgerald Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)Cantor Fitzgerald Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - May 8 at 2:49 PM
Intercept Pharmaceuticals (ICPT) Posts  Earnings Results, Beats Expectations By $0.15 EPSIntercept Pharmaceuticals (ICPT) Posts Earnings Results, Beats Expectations By $0.15 EPS
www.americanbankingnews.com - May 8 at 2:23 PM
Intercept: 1Q Earnings SnapshotIntercept: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:44 AM
Intercept Pharmaceuticals to Post Q1 2018 Earnings of ($3.42) Per Share, Oppenheimer Forecasts (ICPT)Intercept Pharmaceuticals to Post Q1 2018 Earnings of ($3.42) Per Share, Oppenheimer Forecasts (ICPT)
www.americanbankingnews.com - May 7 at 1:16 AM
Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor ConferencesIntercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences
finance.yahoo.com - May 2 at 8:44 AM
Whats in Store for Intercept (ICPT) This Earnings Season?What's in Store for Intercept (ICPT) This Earnings Season?
finance.yahoo.com - May 1 at 8:50 AM
What's in Store for Intercept (ICPT) This Earnings Season?What's in Store for Intercept (ICPT) This Earnings Season?
finance.yahoo.com - May 1 at 8:50 AM
BRIEF-Intercept Pharmaceuticals Says Cos Board Increased Size Of Board From Nine Directors To Ten DirectorsBRIEF-Intercept Pharmaceuticals Says Co's Board Increased Size Of Board From Nine Directors To Ten Directors
www.reuters.com - April 28 at 9:00 AM
BRIEF-Intercept Pharmaceuticals CEO Mark Pruzanskis FY 2017 Total Compensation Was $6.2 MillionBRIEF-Intercept Pharmaceuticals CEO Mark Pruzanski's FY 2017 Total Compensation Was $6.2 Million
www.reuters.com - April 28 at 9:00 AM
Rounds Report: Unlocking Value Of Omeros And InterceptRounds Report: Unlocking Value Of Omeros And Intercept
seekingalpha.com - April 27 at 9:02 AM
Intercept Pharmaceuticals (ICPT) Expected to Post Quarterly Sales of $37.79 MillionIntercept Pharmaceuticals (ICPT) Expected to Post Quarterly Sales of $37.79 Million
www.americanbankingnews.com - April 27 at 2:58 AM

SEC Filings

Intercept Pharmaceuticals (NASDAQ:ICPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intercept Pharmaceuticals (NASDAQ:ICPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intercept Pharmaceuticals (NASDAQ ICPT) Stock Chart for Sunday, June, 17, 2018

Loading chart…

This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.